MRD Testing Market
Report ID: SQMIG20I2807
Report ID: SQMIG20I2807
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG20I2807 |
Region:
Global |
Published Date: April, 2026
Pages:
157
|Tables:
122
|Figures:
77
Global Mrd Testing Market size was valued at USD 2.14 Billion in 2024 and is poised to grow from USD 2.41 Billion in 2025 to USD 2.1 Billion by 2033, growing at a CAGR of 12.8% during the forecast period (2026-2033).
Minimal residual disease testing encompasses sensitive assays that detect levels of cancer cells remaining after treatment and the market has grown because clinicians and developers rely on those measurements to inform therapy and evaluate efficacy. Historically the field began with low-sensitivity microscopy and flow cytometry but evolved through PCR-based methods and next-generation sequencing and circulating tumor DNA assays which increased sensitivity and broadened applications. Because MRD status predicts relapse risk and can shorten or extend therapy its clinical utility has been demonstrated in hematologic malignancies such as acute lymphoblastic leukemia and multiple myeloma which has driven investment and regulatory attention.Among the factors shaping the MRD testing market globally, reimbursement policies and guideline acceptance exert the most direct influence because when payers and professional societies endorse MRD measurement clinicians adopt protocols and health systems invest in laboratory capacity. That adoption causes diagnostic companies to scale assays and form partnerships with pharmaceutical firms which accelerates clinical trials using MRD endpoints and shortens drug development timelines. In practice this dynamic enables oncologists to tailor maintenance strategies in multiple myeloma and to de-escalate therapy in pediatric acute lymphoblastic leukemia while commercial opportunities arise for centralized sequencing labs and decentralized blood-based assays in oncology.
How is AI enhancing accuracy in the MRD testing market?
AI improves accuracy in the MRD testing market by strengthening three core areas: signal detection, interpretation consistency, and data integration. Machine learning models denoise ctDNA sequencing and help separate true residual signals from technical noise. Deep learning applied to flow cytometry and digital pathology automates pattern recognition and reduces subjective variability. AI also fuses molecular data with clinical context to make MRD calls more actionable. The market is shifting toward AI enabled pipelines that speed result turnaround and make MRD outputs more reliable for clinicians and for drug development programs.Adaptive Biotechnologies January 2026, reported strong clonoSEQ adoption, and growing test volumes provide richer datasets that AI models can learn from to refine signal calling and accelerate automated reporting. This real world development supports market growth and greater laboratory efficiency.
Market snapshot - (2026-2033)
Global Market Size
USD 2.14 Billion
Largest Segment
Next-Generation Sequencing (NGS - High Sensitivity)
Fastest Growth
Next-Generation Sequencing (NGS - High Sensitivity)
Growth Rate
12.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global mrd testing market is segmented by technology framework, clinical indication, sample category, end-user facility and region. Based on technology framework, the market is segmented into Next-Generation Sequencing (NGS - High Sensitivity), Flow Cytometry (Multiparametric), Polymerase Chain Reaction (qPCR/ddPCR) and Specialized Imaging & Mass Spectrometry. Based on clinical indication, the market is segmented into Hematological Malignancies (Leukemia, Lymphoma, Multiple Myeloma), Solid Tumors (Breast, Colorectal, Lung Cancer) and Monitoring Post-Stem Cell Transplant. Based on sample category, the market is segmented into Liquid Biopsy (Blood/Plasma), Bone Marrow Aspirate and Tissue-based Biopsy. Based on end-user facility, the market is segmented into Specialized Oncology Hospitals & Cancer Centers, Diagnostic & Genomics Laboratories and Academic & Pharmaceutical Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Next-Generation Sequencing (NGS - High Sensitivity) segment dominates because its deep, high-resolution profiling captures a wide array of low-frequency variants and structural changes critical for reliable MRD detection and prognostication. The method’s compatibility with broad gene panels and advanced bioinformatics enables comprehensive molecular characterization, which informs personalized treatment decisions. Clinical labs favor this approach for its ability to reduce blind spots and support longitudinal monitoring tied to targeted therapy strategies.
However, Polymerase Chain Reaction (qPCR/ddPCR) segment is witnessing the strongest growth momentum as highly sensitive, streamlined assays enable rapid, cost-efficient MRD surveillance in routine clinical workflows. Growing validation in specific disease contexts and simpler laboratory implementation drive adoption, while assay standardization and quicker turnaround expand access and create new opportunities for decentralized, repeat testing and scalable real-world monitoring.
Bone Marrow Aspirate segment dominates because it provides direct access to marrow disease burden, yielding higher tumor cell content and well-established biomarkers that underpin sensitive MRD detection in hematological malignancies. Its entrenched role in diagnostic and response assessment pathways, together with clinician familiarity and procedural integration with cytomorphology and molecular assays, maintains its position as the reference sampling approach for assessing residual disease and guiding treatment intensity.
However, Liquid Biopsy (Blood/Plasma) segment is emerging as the fastest growing area driven by noninvasive serial sampling, improving ctDNA analytics, and clinician demand for real-time monitoring outside invasive procedures. Enhanced assay performance and streamlined collection promote more frequent testing opportunities, enabling wider adoption across disease settings and fueling new applications in longitudinal MRD surveillance and adaptive therapeutic management.
To get detailed segments analysis, Request a Free Sample Report
North America dominates due to a confluence of advanced healthcare infrastructure, concentrated diagnostic expertise, and a robust ecosystem that supports rapid clinical translation. Strong clinical research networks and high-volume laboratory capacity enable efficient validation and scale up of MRD assays. The presence of major diagnostics and biotech companies fosters commercial development and broad distribution, while payor frameworks and clinical guideline development facilitate integration into care pathways. Cross-sector collaboration among industry, academic centers, and regulatory advisors enhances evidence generation and adoption. Emphasis on precision oncology, comprehensive training of specialized personnel, and an established market for novel diagnostics create an environment where MRD testing can move from niche research use into more routine clinical application across hematology and oncology.
MRD Testing Market in the United States benefits from concentration of advanced diagnostics firms, a broad clinical research network, and integration of novel assays into oncology pathways. Payers and health systems support implementation through reimbursement mechanisms, while academic and commercial laboratories provide testing capacity. Collaboration between industry, clinical centers, and regulatory advisors accelerates adoption, creating an ecosystem where technological innovation and clinical demand align to make MRD assessment routine in hematology care.
MRD Testing Market in Canada is characterized by strong public health infrastructure, centralized laboratory networks, and coordinated provincial programs that enable broader access to diagnostic services. Investment in research and partnerships between academic centers and industry supports validation of MRD assays. Policy frameworks and procurement encourage adoption within pathways, while attention to equitable access and integration with cancer strategies positions Canada to expand routine MRD testing across hematology care settings.
The rapid expansion in Europe is driven by increasing alignment of clinical priorities toward precision oncology, strong academic expertise, and collaborative efforts to harmonize assay performance and clinical utility. National and regional initiatives support centralized laboratory capacity and evidence generation that enable MRD integration into care pathways. Diagnostic companies and international manufacturers are strengthening commercial networks, while payor frameworks and professional society advocacy evolve to recognize diagnostic value within treatment decision making. Cross-border research and guideline development foster comparability and clinician confidence, and investments in data infrastructure and workforce training further support implementation. This combination of technical capability, policy engagement, and practical clinician support positions Europe as an active and growing market for MRD adoption and standardization.
MRD Testing Market in Germany is anchored by a strong molecular diagnostics industry, integrated hospital networks, and clinical research centers that support assay development and validation. Payer engagement and clinical guideline influence encourage adoption into hematology pathways, while centralized laboratory services enable sample processing. Collaboration between domestic manufacturers and global partners, with a focus on standardization and quality assurance, positions Germany as market for routine MRD implementation across therapeutic areas.
MRD Testing Market in the United Kingdom is supported by genomic medicine initiatives, centralized sequencing hubs, and NHS engagement that enables pilot implementations and pathway integration. Academic partnerships drive clinical validation and guideline development, while industry collaboration supports assay availability. Emphasis on workforce training, data integration, and pragmatic reimbursement approaches increases clinician uptake, positioning the United Kingdom as a growing market for routine MRD assessment across hematology and oncology care.
MRD Testing Market in France is shaped by centralized healthcare structures, academic research in oncology, and coordination by national cancer agencies that promote evidence generation and clinical integration. Hospital networks and reference laboratories support standardization and scalability of assays, while public-private partnerships accelerate transfer. Focus on clinical validation, quality assurance, and integration with treatment protocols helps position France as emerging market for routine MRD testing across hematology and oncology services.
Asia Pacific is strengthening its position through targeted investments in molecular diagnostics, expansion of clinical research capacity, and closer collaboration between industry and academic centers. Regulatory pathways are evolving to better support diagnostic innovation, while regional manufacturers align with international quality standards and expand commercial reach. Health systems are building centralized laboratory networks and genomic initiatives to integrate MRD into oncology care, accompanied by programs to train laboratory personnel and harmonize assay performance. Cross-border clinical collaborations and export-oriented commercialization strategies enhance technology diffusion, and digital infrastructure investments improve data sharing and comparability. Together, these factors are driving broader validation and adoption of MRD testing across diverse healthcare systems in the region.
MRD Testing Market in Japan benefits from a robust diagnostics industry, advanced hospital infrastructure, and translational research that supports assay development and clinical validation. National precision medicine and genomic initiatives enable integration of MRD assessment into oncology workflows, while regulatory and reimbursement frameworks support commercialization. Collaboration between academic centers and industry, with focus on quality assurance and standardized protocols, positions Japan as market for routine MRD implementation across cancer care.
MRD Testing Market in South Korea is supported by a dynamic diagnostics sector, biotech clusters, and government programs that encourage innovation and clinical adoption. Hospitals and reference laboratories provide capacity for assay validation and broader testing, while export orientation drives quality alignment with international standards. Collaborative networks between academia and industry, with investments in workforce training and data infrastructure, help position South Korea as an influential market for MRD assessment.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Adoption Of Molecular Diagnostics
Advancements In Sequencing Technologies
High Cost Of Advanced Assays
Limited Standardization and Guidelines
Request Free Customization of this report to help us to meet your business objectives.
The MRD testing competitive landscape is consolidation and platform partnering driven, with incumbent diagnostics and niche entrants using M&A, co-development and instrument-led rollouts to win clinical adoption. Examples include Quest Diagnostics acquiring Haystack Oncology April 27, 2023 and QIAGEN forming partnerships to embed partner assays on its QIAcuity platform June 2, 2025 while tools innovators commercialize novel high-sensitivity platforms.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global MRD testing market is positioned for robust growth driven by rising adoption of molecular diagnostics, with North America dominating due to advanced infrastructure and strong clinical networks. The NGS high-sensitivity segment is the leading technology because of deep variant detection and comprehensive molecular profiling. A key driver is clinician demand for sensitive, longitudinal monitoring and a second driver is continuous advancements in sequencing technologies that improve sensitivity and bioinformatics. However, a major restraint remains the high cost of advanced assays and supporting infrastructure, which limits uptake in resource-constrained settings and slows widespread standardization and routine implementation.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.14 Billion |
| Market size value in 2033 | USD 2.1 Billion |
| Growth Rate | 12.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the MRD Testing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the MRD Testing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the MRD Testing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the MRD Testing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
